Over 50 Years of Specialty Injectables
American Regent develops, manufactures and supplies high-quality sterile injectables for healthcare providers and their patients.
Dedicated to Alleviating Drug Shortages
We are committed to collaborating with the FDA to prevent or mitigate drug shortages that impact the health of patients.
Check Product Availability
Updated January 18, 2022 08:50 AM
Melville, NY – September 2, 2021: American Regent, Inc. introduces FDA-approved Multrys™ (trace elements injection 4*, USP). Multrys™ is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Pediatric Patients with Iron Deficiency Anemia
For patients as young as one year of age who have intolerance to, or have had an unsatisfactory response to, oral iron, Injectafer may now be administered for IDA treatment1
Basking Ridge, N.J. and Shirley, N.Y. (December 15, 2021) – Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved Injectafer for pediatric patients (who are 1 year of age or older) with iron deficiency anemia (IDA) who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.
The program offers fellowships in both Medical Affairs & Pharmaceutical Marketing and in Clinical Research & Development.